| Literature DB >> 24052547 |
Csaba Bödör1, Vera Grossmann, Nikolay Popov, Jessica Okosun, Ciarán O'Riain, King Tan, Jacek Marzec, Shamzah Araf, Jun Wang, Abigail M Lee, Andrew Clear, Silvia Montoto, Janet Matthews, Sameena Iqbal, Hajnalka Rajnai, Andreas Rosenwald, German Ott, Elias Campo, Lisa M Rimsza, Erlend B Smeland, Wing C Chan, Rita M Braziel, Louis M Staudt, George Wright, T Andrew Lister, Olivier Elemento, Robert Hills, John G Gribben, Claude Chelala, András Matolcsy, Alexander Kohlmann, Torsten Haferlach, Randy D Gascoyne, Jude Fitzgibbon.
Abstract
Gain of function mutations in the H3K27 methyltransferase EZH2 represent a promising therapeutic target in germinal center lymphomas. In this study, we assessed the frequency and distribution of EZH2 mutations in a large cohort of patients with follicular lymphoma (FL) (n = 366) and performed a longitudinal analysis of mutation during the disease progression from FL to transformed FL (tFL) (n = 33). Mutations were detected at 3 recurrent mutation hot spots (Y646, A682, and A692) in 27% of FL cases with variant allele frequencies (VAF) ranging from 2% to 61%. By comparing VAF of EZH2 with other mutation targets (CREBBP, MLL2, TNFRSF14, and MEF2B), we were able to distinguish patients harboring clonal EZH2 mutation from rarer cases with subclonal mutations. Overall, the high incidence of EZH2 mutations in FL and their stability during disease progression makes FL an appropriate disease to evaluate EZH2 targeted therapy.Entities:
Mesh：
Substances：
Year: 2013 PMID： 24052547 PMCID： PMC3814734 DOI： 10.1182/blood-2013-04-496893
Source DB: PubMed Journal: Blood ISSN： 0006-4971 Impact factor: 22.113